查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1658718

全球生物製藥第三方物流(3PL) 市場依產品類型、供應鏈、服務類型、地區、趨勢分析、競爭格局、預測（2019-2031 年）

Biopharmaceutical Third Party Logistics Market, By Product Type; By Supply Chain; By Service Type; By Region, Global Trend Analysis, Competitive Landscape & Forecast, 2019-2031
出版日期: | 出版商: Blueweave Consulting | 英文 550 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

全球生物製藥第三方物流(3PL) 市場規模的主要推動因素是生物製藥需求激增、低溫運輸物流蓬勃發展、全球醫療保健行業不斷擴大、對法規合規性的重視以及技術進步的日益採用。

以金額為準，全球生物製藥第三方物流(3PL) 市場規模估計到 2024 年將達到 1,306 億美元。預計到 2031 年將達到 1,890 億美元，在 2025-2031 年預測期內以 5.6% 的健康複合年成長率成長。推動市場發展的因素包括對溫度敏感生技藥品的需求不斷成長、生物製藥供應鏈日益全球化以及為提高效率和成本效益而不斷上升的外包趨勢。藥品安全和品質的嚴格監管要求、低溫運輸物流技術的進步以及不斷擴張的生物製藥行業進一步推動了市場的成長。此外，對生技藥品、疫苗和特殊藥物的需求激增以及對專業化處理和分銷的需求正在推動全球生物製藥第三方物流服務市場的成長。

機會－數位科技的日益普及

全球生物製藥第三方物流(3PL) 市場由數位技術的日益採用所推動，這些技術提高了供應鏈的效率和透明度。物聯網、人工智慧、區塊鏈和資料分析等先進解決方案最佳化了即時追蹤、溫度監控和庫存管理，以確保敏感生物製藥產品的完整性。先進的技術有助於提高業務效率、降低風險並支援法規遵循性，滿足生物製藥產業對安全高效物流解決方案日益成長的需求。

生技藥品產品類型細分市場主導全球生物製藥第三方物流市場

生技藥品是全球生物製藥第三方物流（3PL）市場的主要產品類型。生技藥品在市場上佔據主導地位，是由於對溫度敏感的生技藥品的需求不斷增加，這些生物製劑需要專門的儲存和運輸解決方案。複雜的處理要求、嚴格的法規遵循以及越來越多的慢性病生物療法促進了這一領域的擴張。此外，低溫運輸物流的進步和新興市場對生技藥品的日益採用，進一步提升了該領域在全球第三方物流領域的地位。

地緣政治緊張局勢加劇對全球生物製藥第三方物流(3PL) 市場的影響

全球生物製藥第三方物流(3PL) 市場透過提高生物製藥分銷的效率、可靠性和成本效益，對醫療保健供應鏈產生了重大影響。我們也支持溫度敏感產品的處理，透過先進的低溫運輸物流確保生技藥品、疫苗和特殊藥品的完整性。 3PL 供應商提供倉儲、庫存管理、法規合規和即時追蹤等專業服務，以簡化製藥公司的業務。這使得生物製藥公司能夠更快進入市場、降低營運成本並專注於研發等核心業務。此外，全球對生技藥品、個人化醫療和醫療保健的需求不斷成長，正在推動市場擴張。第三方物流產業也透過採用數位技術、自動化和資料分析來推動創新，以在日益複雜的全球環境中提高供應鏈的可視性和彈性。

競爭格局

全球生物製藥第三方物流（3PL）市場高度分散，有大量公司參與市場。主導市場的主要企業有：DHL International GmbH、順豐速遞、美國聯合包裹服務公司 (UPS)、AmerisourceBergen Corp、DB Schenker、Kuehne and Nagel、嘉里物流網路有限公司、Agility 等。公司採用的關鍵行銷策略是設施擴建、產品多樣化、聯盟、合作、夥伴關係、收購等，以擴大客戶範圍並在全球生物製藥第三方物流(3PL) 市場的競爭中獲得競爭優勢。

本報告對全球生物製藥第三方物流（3PL）市場進行了深入分析，並提供了有關成長潛力和未來趨勢的資訊。它還分析了市場的成長動力、挑戰和競爭動態。

目錄

第1章 調查框架

第 2 章執行摘要

第 3 章全球生物製藥第三者物流(3PL)市場考察考量

  • 產業價值鏈分析
  • DROC 分析
    • 成長動力
      • 技術進步
      • 對溫度敏感產品的需求不斷增加
      • 醫療全球化
    • 限制因素
      • 嚴格遵守法規
      • 初期投資高
    • 機會
      • 採用數位技術
      • 外包趨勢
    • 任務
      • 操作風險
      • 市場競爭
  • 科技進步/最新發展
  • 法規結構
  • 波特五力分析

第 4 章：全球生物製藥第三方物流(3PL) 行銷策略

第 5 章全球生物製藥第三方物流(3PL) 市場：定價分析

第6章全球生物製藥第三方物流(3PL) 市場概述

  • 市場規模及預測（2019-2031）
    • 金額
  • 市場佔有率和預測
    • 依產品類型
      • 疫苗
      • 生技藥品
      • 血漿療法
    • 按供應鏈
      • 低溫運輸物流
      • 非低溫運輸物流
    • 按服務類型
      • 運輸
      • 倉儲和儲存
    • 按地區
      • 北美洲
      • 歐洲
      • 亞太地區
      • 拉丁美洲
      • 中東和非洲

7. 北美生物製藥第三方物流(3PL) 市場

  • 市場規模及預測（2019-2031）
    • 金額
  • 市場佔有率和預測
    • 依產品類型
    • 按供應鏈
    • 按服務類型
    • 按國家
      • 美國
      • 加拿大

8. 歐洲生物製藥第三方物流(3PL) 市場

  • 市場規模及預測（2019-2031）
    • 金額
  • 市場佔有率和預測
    • 依產品類型
    • 按供應鏈
    • 按服務類型
    • 按國家
      • 德國
      • 英國
      • 義大利
      • 法國
      • 西班牙
      • 比利時
      • 俄羅斯
      • 荷蘭
      • 歐洲其他地區

9. 亞太生物製藥第三人物流(3PL) 市場

  • 市場規模及預測（2019-2031）
    • 金額
  • 市場佔有率和預測
    • 依產品類型
    • 按供應鏈
    • 按服務類型
    • 按國家
      • 中國
      • 印度
      • 日本
      • 韓國
      • 澳洲和紐西蘭
      • 印尼
      • 馬來西亞
      • 新加坡
      • 越南
      • 其他亞太地區

10. 拉丁美洲生物製藥第三方物流(3PL) 市場

  • 市場規模及預測（2019-2031）
    • 金額
  • 市場佔有率和預測
    • 依產品類型
    • 按供應鏈
    • 按服務類型
    • 按國家
      • 巴西
      • 墨西哥
      • 阿根廷
      • 秘魯
      • 其他拉丁美洲國家

第 11 章中東和非洲生物製藥第三方物流(3PL) 市場

  • 市場規模及預測（2019-2031）
    • 金額
  • 市場佔有率和預測
    • 依產品類型
    • 按供應鏈
    • 按服務類型
    • 按國家
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 科威特
      • 南非
      • 奈及利亞
      • 阿爾及利亞
      • 其他中東和非洲地區

第12章 競爭格局

  • 主要企業及其產品列表
  • 全球生物製藥第三方物流(3PL) 市場公司市場佔有率分析（2024 年）
  • 競爭性基準化分析：根據業務參數
  • 重大策略發展（合併、收購、聯盟）

第 13 章地緣政治緊張局勢加劇對全球生物製藥第三方物流(3PL) 市場的影響

第 14 章 公司簡介（公司概況、財務矩陣、競爭格局、關鍵人員、主要競爭對手、聯繫、策略展望、SWOT 分析）

  • DHL International GmbH
  • SF Express
  • United Parcel Service of America Inc. (UPS)
  • AmerisourceBergen Corp.
  • DB Schenker
  • Kuehne and Nagel
  • Kerry Logistics Network Ltd
  • Agility
  • 其他知名公司

第 15 章 關鍵策略建議

第16章調查方法

簡介目錄
Product Code: BWC25078

Global Biopharmaceutical Third Party Logistics (3PL) Market to Reach USD 189 Billion by 2031

Global Biopharmaceutical Third Party Logistics (3PL) Market is booming primarily due to a surging demand for biopharmaceuticals, thriving cold chain logistics, expanding global healthcare sector, an increasing focus on complying with regulations, and the growing adoption of technological advancements.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated Global Biopharmaceutical Third Party Logistics (3PL) Market size by value at USD 130.6 billion in 2024. During the forecast period between 2025 and 2031, BlueWeave expects Global Biopharmaceutical Third Party Logistics (3PL) Market size to boom at a robust CAGR of 5.6% reaching a value of USD 189 billion by 2031. The Global Market for Biopharmaceutical Third Party Logistics (3PL) is driven by the rising demand for temperature-sensitive biologics, increasing globalization of biopharmaceutical supply chains, and growing outsourcing trends to enhance efficiency and cost-effectiveness. Stringent regulatory requirements for drug safety and quality, advancements in cold chain logistics technologies, and the expansion of the biopharmaceutical industry further propel market growth. Additionally, the surging demand for biologics, vaccines, and specialty drugs, along with the need for specialized handling and distribution, boosts the growth of Global Biopharmaceutical 3PL Services Market.

Opportunity - Growing Adoption of Digital Technologies

Global Biopharmaceutical Third Party Logistics (3PL) Market is driven by the growing adoption of digital technologies, enhancing supply chain efficiency and transparency. Advanced solutions like IoT, AI, blockchain, and data analytics optimize real-time tracking, temperature monitoring, and inventory management, ensuring the integrity of sensitive biopharmaceutical products. Advanced technologies help in improving operational efficiency, reducing risks, and supporting regulatory compliance, meeting the growing demand for secure and efficient logistics solutions in the biopharmaceutical industry.

Biologics Product Type Segment Dominates Global Biopharma 3PL Market

The biologics segment is the leading product type in Global Biopharmaceutical Third Party Logistics (3PL) Market. Biologics' market dominance is driven by an increasing demand for temperature-sensitive biologic drugs, requiring specialized storage and transportation solutions. The complex handling requirements, strict regulatory compliance, and growth in biologic therapies for chronic diseases contribute to the segment's expansion. Additionally, advancements in cold chain logistics and the rising adoption of biologics in emerging markets further boost this segment's prominence in the global 3PL landscape.

Impact of Escalating Geopolitical Tensions on Global Biopharmaceutical Third Party Logistics (3PL) Market

Global Biopharmaceutical Third-Party Logistics (3PL) Market significantly impacts the healthcare supply chain by enhancing the efficiency, reliability, and cost-effectiveness of biopharmaceutical distribution. It supports temperature-sensitive product handling, ensuring the integrity of biologics, vaccines, and specialty drugs through advanced cold chain logistics. 3PL providers offer specialized services like warehousing, inventory management, regulatory compliance, and real-time tracking, which streamline operations for pharmaceutical companies. It enables faster market access, reduces operational costs, and allows biopharma firms to focus on core activities like R&D. Additionally, the growing demand for biologics, personalized medicine, and global healthcare access has driven the market's expansion. The 3PL sector also fosters innovation through the adoption of digital technologies, automation, and data analytics, enhancing supply chain visibility and resilience in an increasingly complex global environment.

Competitive Landscape

Global Biopharmaceutical Third Party Logistics (3PL) Market is highly fragmented, with numerous players serving the market. Major companies dominating the market include DHL International GmbH, SF Express, United Parcel Service of America Inc. (UPS), AmerisourceBergen Corp, DB Schenker, Kuehne and Nagel, Kerry Logistics Network Ltd, and Agility. The key marketing strategies adopted by the players are facility expansion, product diversification, alliances, collaborations, partnerships, and acquisitions to expand their customer reach and gain a competitive edge over their competitors in Global Biopharmaceutical Third Party Logistics (3PL) Market.

The report's in-depth analysis provides information about growth potential, upcoming trends, and Global Biopharmaceutical Third Party Logistics (3PL) Market statistics. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Biopharmaceutical Third Party Logistics (3PL) Market along with industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyses the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Executive Summary

3. Global Biopharmaceutical Third Party Logistics (3PL)Market Insights

  • 3.1. Industry Value Chain Analysis
  • 3.2. DROC Analysis
    • 3.2.1. Growth Drivers
      • 3.2.1.1. Technological Advancements
      • 3.2.1.2. Increasing Demand for Temperature-Sensitive Products
      • 3.2.1.3. Globalization of Healthcare
    • 3.2.2. Restraints
      • 3.2.2.1. Stringent Regulatory Compliance
      • 3.2.2.2. High Initial Investment
    • 3.2.3. Opportunities
      • 3.2.3.1. Adoption of Digital Technologies
      • 3.2.3.2. Outsourcing Trends
    • 3.2.4. Challenges
      • 3.2.4.1. Operational Risks
      • 3.2.4.2. Market Competition
  • 3.3. Technological Advancements/Recent Developments
  • 3.4. Regulatory Framework
  • 3.5. Porter's Five Forces Analysis
    • 3.5.1. Bargaining Power of Suppliers
    • 3.5.2. Bargaining Power of Buyers
    • 3.5.3. Threat of New Entrants
    • 3.5.4. Threat of Substitutes
    • 3.5.5. Intensity of Rivalry

4. Global Biopharmaceutical Third Party Logistics (3PL)Marketing Strategies

5. Global Biopharmaceutical Third Party Logistics (3PL)Market: Pricing Analysis

6. Global Biopharmaceutical Third Party Logistics (3PL)Market Overview

  • 6.1. Market Size & Forecast, 2019-2031
    • 6.1.1. By Value (USD Million)
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
      • 6.2.1.1. Vaccines
      • 6.2.1.2. Biologics
      • 6.2.1.3. Blood Plasma-based Therapies
    • 6.2.2. By Supply Chain
      • 6.2.2.1. Cold Chain Logistics
      • 6.2.2.2. Non-Cold Chain Logistics
    • 6.2.3. By Service Type
      • 6.2.3.1. Transportation
      • 6.2.3.2. Warehousing & Storage
    • 6.2.4. By Region
      • 6.2.4.1. North America
      • 6.2.4.2. Europe
      • 6.2.4.3. Asia Pacific (APAC)
      • 6.2.4.4. Latin America (LATAM)
      • 6.2.4.5. Middle East and Africa (MEA)

7. North America Biopharmaceutical Third Party Logistics (3PL) Market

  • 7.1. Market Size & Forecast, 2019-2031
    • 7.1.1. By Value (USD Billion)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By Supply Chain
    • 7.2.3. By Service Type
    • 7.2.4. By Country
      • 7.2.4.1. United States
      • 7.2.4.1.1. By Product Type
      • 7.2.4.1.2. By Supply Chain
      • 7.2.4.1.3. By Service Type
      • 7.2.4.2. Canada
      • 7.2.4.2.1. By Product Type
      • 7.2.4.2.2. By Supply Chain
      • 7.2.4.2.3. By Service Type

8. Europe Biopharmaceutical Third Party Logistics (3PL) Market

  • 8.1. Market Size & Forecast, 2019-2031
    • 8.1.1. By Value (USD Billion)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By Supply Chain
    • 8.2.3. By Service Type
    • 8.2.4. By Country
      • 8.2.4.1. Germany
      • 8.2.4.1.1. By Product Type
      • 8.2.4.1.2. By Supply Chain
      • 8.2.4.1.3. By Service Type
      • 8.2.4.2. United Kingdom
      • 8.2.4.2.1. By Product Type
      • 8.2.4.2.2. By Supply Chain
      • 8.2.4.2.3. By Service Type
      • 8.2.4.3. Italy
      • 8.2.4.3.1. By Product Type
      • 8.2.4.3.2. By Supply Chain
      • 8.2.4.3.3. By Service Type
      • 8.2.4.4. France
      • 8.2.4.4.1. By Product Type
      • 8.2.4.4.2. By Supply Chain
      • 8.2.4.4.3. By Service Type
      • 8.2.4.5. Spain
      • 8.2.4.5.1. By Product Type
      • 8.2.4.5.2. By Supply Chain
      • 8.2.4.5.3. By Service Type
      • 8.2.4.6. Belgium
      • 8.2.4.6.1. By Product Type
      • 8.2.4.6.2. By Supply Chain
      • 8.2.4.6.3. By Service Type
      • 8.2.4.7. Russia
      • 8.2.4.7.1. By Product Type
      • 8.2.4.7.2. By Supply Chain
      • 8.2.4.7.3. By Service Type
      • 8.2.4.8. The Netherlands
      • 8.2.4.8.1. By Product Type
      • 8.2.4.8.2. By Supply Chain
      • 8.2.4.8.3. By Service Type
      • 8.2.4.9. Rest of Europe
      • 8.2.4.9.1. By Product Type
      • 8.2.4.9.2. By Supply Chain
      • 8.2.4.9.3. By Service Type

9. Asia Pacific Biopharmaceutical Third Party Logistics (3PL) Market

  • 9.1. Market Size & Forecast, 2019-2031
    • 9.1.1. By Value (USD Billion)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By Supply Chain
    • 9.2.3. By Service Type
    • 9.2.4. By Country
      • 9.2.4.1. China
      • 9.2.4.1.1. By Product Type
      • 9.2.4.1.2. By Supply Chain
      • 9.2.4.1.3. By Service Type
      • 9.2.4.2. India
      • 9.2.4.2.1. By Product Type
      • 9.2.4.2.2. By Supply Chain
      • 9.2.4.2.3. By Service Type
      • 9.2.4.3. Japan
      • 9.2.4.3.1. By Product Type
      • 9.2.4.3.2. By Supply Chain
      • 9.2.4.3.3. By Service Type
      • 9.2.4.4. South Korea
      • 9.2.4.4.1. By Product Type
      • 9.2.4.4.2. By Supply Chain
      • 9.2.4.4.3. By Service Type
      • 9.2.4.5. Australia and New Zealand
      • 9.2.4.5.1. By Product Type
      • 9.2.4.5.2. By Supply Chain
      • 9.2.4.5.3. By Service Type
      • 9.2.4.6. Indonesia
      • 9.2.4.6.1. By Product Type
      • 9.2.4.6.2. By Supply Chain
      • 9.2.4.6.3. By Service Type
      • 9.2.4.7. Malaysia
      • 9.2.4.7.1. By Product Type
      • 9.2.4.7.2. By Supply Chain
      • 9.2.4.7.3. By Service Type
      • 9.2.4.8. Singapore
      • 9.2.4.8.1. By Product Type
      • 9.2.4.8.2. By Supply Chain
      • 9.2.4.8.3. By Service Type
      • 9.2.4.9. Vietnam
      • 9.2.4.9.1. By Product Type
      • 9.2.4.9.2. By Supply Chain
      • 9.2.4.9.3. By Service Type
      • 9.2.4.10. Rest of APAC
      • 9.2.4.10.1. By Product Type
      • 9.2.4.10.2. By Supply Chain
      • 9.2.4.10.3. By Service Type

10. Latin America Biopharmaceutical Third Party Logistics (3PL) Market

  • 10.1. Market Size & Forecast, 2019-2031
    • 10.1.1. By Value (USD Billion)
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Type
    • 10.2.2. By Supply Chain
    • 10.2.3. By Service Type
    • 10.2.4. By Country
      • 10.2.4.1. Brazil
      • 10.2.4.1.1. By Product Type
      • 10.2.4.1.2. By Supply Chain
      • 10.2.4.1.3. By Service Type
      • 10.2.4.2. Mexico
      • 10.2.4.2.1. By Product Type
      • 10.2.4.2.2. By Supply Chain
      • 10.2.4.2.3. By Service Type
      • 10.2.4.3. Argentina
      • 10.2.4.3.1. By Product Type
      • 10.2.4.3.2. By Supply Chain
      • 10.2.4.3.3. By Service Type
      • 10.2.4.4. Peru
      • 10.2.4.4.1. By Product Type
      • 10.2.4.4.2. By Supply Chain
      • 10.2.4.4.3. By Service Type
      • 10.2.4.5. Rest of LATAM
      • 10.2.4.5.1. By Product Type
      • 10.2.4.5.2. By Supply Chain
      • 10.2.4.5.3. By Service Type

11. Middle East and Africa Biopharmaceutical Third Party Logistics (3PL) Market

  • 11.1. Market Size & Forecast, 2019-2031
    • 11.1.1. By Value (USD Billion)
  • 11.2. Market Share & Forecast
    • 11.2.1. By Product Type
    • 11.2.2. By Supply Chain
    • 11.2.3. By Service Type
    • 11.2.4. By Country
      • 11.2.4.1. Saudi Arabia
      • 11.2.4.1.1. By Product Type
      • 11.2.4.1.2. By Supply Chain
      • 11.2.4.1.3. By Service Type
      • 11.2.4.2. UAE
      • 11.2.4.2.1. By Product Type
      • 11.2.4.2.2. By Supply Chain
      • 11.2.4.2.3. By Service Type
      • 11.2.4.3. Qatar
      • 11.2.4.3.1. By Product Type
      • 11.2.4.3.2. By Supply Chain
      • 11.2.4.3.3. By Service Type
      • 11.2.4.4. Kuwait
      • 11.2.4.4.1. By Product Type
      • 11.2.4.4.2. By Supply Chain
      • 11.2.4.4.3. By Service Type
      • 11.2.4.5. South Africa
      • 11.2.4.5.1. By Product Type
      • 11.2.4.5.2. By Supply Chain
      • 11.2.4.5.3. By Service Type
      • 11.2.4.6. Nigeria
      • 11.2.4.6.1. By Product Type
      • 11.2.4.6.2. By Supply Chain
      • 11.2.4.6.3. By Service Type
      • 11.2.4.7. Algeria
      • 11.2.4.7.1. By Product Type
      • 11.2.4.7.2. By Supply Chain
      • 11.2.4.7.3. By Service Type
      • 11.2.4.8. Rest of MEA
      • 11.2.4.8.1. By Product Type
      • 11.2.4.8.2. By Supply Chain
      • 11.2.4.8.3. By Service Type

12. Competitive Landscape

  • 12.1. List of Key Players and Their Offerings
  • 12.2. Global Biopharmaceutical Third Party Logistics (3PL) Market Company Market Share Analysis, 2024
  • 12.3. Competitive Benchmarking, By Operating Parameters
  • 12.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships)

13. Impact of Escalating Geopolitical Tensions on Global Biopharmaceutical Third Party Logistics (3PL) Market

14. Company Profiles (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)

  • 14.1. DHL International GmbH
  • 14.2. SF Express
  • 14.3. United Parcel Service of America Inc. (UPS)
  • 14.4. AmerisourceBergen Corp.
  • 14.5. DB Schenker
  • 14.6. Kuehne and Nagel
  • 14.7. Kerry Logistics Network Ltd
  • 14.8. Agility
  • 14.9. Other Prominent Players

15. Key Strategic Recommendations

16. Research Methodology

  • 16.1. Qualitative Research
    • 16.1.1. Primary & Secondary Research
  • 16.2. Quantitative Research
  • 16.3. Market Breakdown & Data Triangulation
    • 16.3.1. Secondary Research
    • 16.3.2. Primary Research
  • 16.4. Breakdown of Primary Research Respondents, By Region
  • 16.5. Assumptions & Limitations

*Financial information of non-listed companies can be provided as per availability.

**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable